Amgen Inc. AMGN

414.61 8.57 2.11% as of 25 Sep
Market cap
$219.1B
P/E
25.6×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Amgen Inc. (AMGN) Debt to equity

Amgen Inc.'s debt to equity at the end of the quarter to 30 June 2026 was 4.9×, down 1.4× from fiscal 2025 (6.3×). Over the past ten years it has ranged from 1.1× (fiscal 2015) to 10.6× (fiscal 2022); the current reading is higher than 73% of that period. That is above the Drug Manufacturers General industry median of 0.6× and above the Healthcare sector median of 0.0×.

Debt to equity, annual

Annual

Period Debt to equity Change
FY2025 6.3× (38.33%)
FY2024 10.2× (1.37%)
FY2023 10.4× (2.54%)
FY2022 10.6× 113.98%
FY2021 5.0× 41.81%
FY2020 3.5× 13.40%
FY2019 3.1× 13.89%
FY2018 2.7× 93.85%
FY2017 1.4× 20.92%
FY2016 1.2× 3.48%

Quarterly

Period Debt to equity Change
Jun 2026 4.9× (21.40%)
Mar 2026 6.2× (1.10%)
Dec 2025 6.3× 11.13%
Sep 2025 5.7× (25.00%)
42 more quarters

Against its own ten years

Low 1.1× High 10.6×
Ten-year median 3.5×
Current reading's percentile 73

Debt to equity against peers

Company Debt to equity
ABBV AbbVie Inc. compare −12.0×
AZN AstraZeneca PLC compare 0.6×
NVO Novo Nordisk A/S compare 0.6×
PFE Pfizer Inc. compare 0.7×
NVS Novartis AG compare 1.1×
MRK Merck & Co., Inc. compare 1.2×
BMY Bristol Myers Squibb Company compare 1.9×
GILD Gilead Sciences, Inc. compare 2.2×
AMGN Amgen Inc. 4.9×
Drug Manufacturers General industry median 0.6×
Healthcare sector median 0.0×
Market median 0.2×

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

More on AMGN